

Corrected Replacement Pages for IDS
filed 5/2/06 - PAGES 1-4

DATE: October 31, 2003

SHEET 1 of 4

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6789.US.D1	SERIAL NO. 10/699465
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S) M. D. Cowart, et al.	
(Use several sheets if necessary)		FILING DATE October 31, 2003	GROUP
(37 CFR 1.98 (b))			

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
EB	A1	5,714,854	02/03/98	Mizuta et al.			
EB	A2	5,792,768	08/11/98	Kulagowski et al.			
EB	A3	3,472,854	10/14/69	Archer			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICA-TION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EB	C1	Andersson, K. et al., "Physiology of penile erection," Physiol. Rev. 75:191-236 (1995) (1995).
	C2	Bendele, A.M. et al., "Anti-Inflammatory Activity of Pergolide, a Dopamine Receptor Agonist," Journal of Pharmacology and Experimental Therapeutics 259(1):169-175 (1991)
	C3	Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977)
	C4	Chen, F.F. et al., "Effects of dopamine, Apomorphine, -Hydroxybutyric Acid, Haloperidol and Pimozide on Reflex Bradycardia in Rats," Journal of Pharmacology and Experimental Therapeutics 214(2):427-432 (1980)
	C5	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)
	C6	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," Urology 56:130-135 (2000)
	C7	Hahn, R.A. et al., "Primate Cardiovascular Responses Mediated by Dopamine Receptors: Effects of N, N-di-n-Propyl dopamine and LY171555," Journal of Pharmacology and Experimental therapeutics 229(1):132-138 (1984)
	C8	Harris, M. C. et al., "Sequential N-Arylation of Primary Amines as a Route to Alkyldiarylamines," J. Org. Chem. 64:6019-6022 (1999)
	C9	Hrib, N. J., et al., "The dopamine D ₄ -receptor: a controversial therapeutic target," Drugs of the Future 2000 25(6):587-611
	C10	Koch, V. et al., "Chemistry of 3-Hydroxypyridien part 2: Synthesis of 5,6-Dihalo-3hydroxypyridines," Synthesis 499-501 (1990)
	C11	Lissoni, et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia," Neuroendocrinology Letters ISSN 21:405-408 (2000)
	C12	Lynch, J.K. et al., "Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic," Tetrahedron: Asymmetry 9:2791-2794 (1998)
	C13	Melis, M et al., "Dopamine and Sexual Behavior," Neuroscience and Biobehavioral Reviews, 19(1):193-35 (1995)

DATE: October 31, 2003

SHEET 2 of 4

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
6789.US.D1SERIAL NO. 10/699465
(not yet assigned)INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)
M. D. Cowart, et al.FILING DATE
October 31, 2003GROUP
(not yet assigned)

(37 CFR 1.98 (b))

<i>EB</i>	C14	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 (1998)
	C15	Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998)
	C16	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)
	C17	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest Drugs, 2:283-302 (2000)
	C18	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)
	C19	Primus, R. et al., "Localization and characterization of dopamine D ₄ binding sites in rat and human brain by use of the novel D ₄ receptor-selective ligand [³ H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997)
	C20	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6)-substituted benzimidazoles," Bull. Hoffmann Inst. 6(2):62-64 (1978)
	C21	Suzuki, M. et al., "D ₃ dopamine receptor mRNA is widely express in human brain," Brain Res 779:58-74 (1998)
	C22	Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000)
	C23	Wagaw, S. et al., "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," J. Org. Chem 61:7240-7241 (1996)
	C24	Yang B. et al., "Palladium-catalyzed amination of aryl halides and sulfonates," Journal of Organometallic Chemistry 576:125-146 (1999)
<i>↓</i>	C25	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)

EXAMINER

E. Barnhardo

DATE CONSIDERED

4/28/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: October 31, 2003 SHEET 3 of 4

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6789.US.D1	SERIAL NO. <i>10/699408</i>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S) M.D. Cowart, et al.	
(Use several sheets if necessary)		FILING DATE October 31, 2003	GROUP
(37 CFR 1.98 (b))			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
<i>EB</i>	98/31368	23.07.98	WO			
	00/23056	27.04.00	WO			
<i>C</i>	0 882 718	09.12.98	EP			
	0 468 884	24.07.91	EP			X
<i>↓</i>	2 154 605	14.09.99	ES			X

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>EB</i>	Bivalacqua et al., "Pharmacotherapy for erectile dysfunction," TIPS 21:484-489 (2000)

EXAMINER *E Benhaddou* DATE CONSIDERED *4/28/04*

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: October 31, 2003 **SHEET 4 of 4**

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6789.US.D1	SERIAL NO. 16/699465
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT(S) M.D. Cowart, et al.	FILING DATE October 31, 2003
			GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
EB	3,362,956	01/09/68	Archer	—	—	
EB	5,714,498	02/03/98	Kulagowski et al	—	—	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

FOREIGN PATENT OR PUBLICATION						
	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
<i>02-B</i>	02/88093	07.11.02	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>E.B.</i>	Shvedov et al., "Catalytic alkylation of amines with alcohols," Zhurnal Organicheskoi Khimii 6(9):1838-1840 (1970)
<i>E.B.</i>	Pugsley et al., "The discovery of PD89211 and related compounds: selective dopamine D4 receptor antagonists," Progress in Neuro-Psychopharmacology & Biological Psychiatry 26(2):219-226 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)